Shewanella xiamenensis, a newly established species originally from sea sediments, was repeatedly recovered from peripancreatic drainages in a patient and was the probable pathogen of hospital-acquired peripancreatic infection. A commercially available system misidentified it as Shewanella putrefaciens, suggesting that some previous reported cases with S. putrefaciens infection might have been caused by other Shewanella species. Precise species identification of Shewanella species usually requires gyrB sequencing.
Introduction
Shewanella xiamenensis is a newly established species of the genus Shewanella; the type strain of this species was found in costal sea sediments off Xiamen, Fujian province, China (Huang et al., 2010) . Although Shewanella species, especially Shewanella algae and Shewanella putrefaciens, have been recognized as human pathogens, there appear to have been no reports of the isolation of S. xiamenensis from any clinical samples and this species has not previously been documented as a cause of infection. However, a case of hospital-acquired infection associated with S. xiamenensis was recently encountered and is reported here.
Case report
A 66-year-old male patient was admitted to West China Hospital on June 2010 due to abdominal pain, distention and vomiting for 1 week. He had been diagnosed with acute pancreatitis associated with gallstones 50 days previously in this hospital, following the criteria proposed by Banks et al. (2006) . His symptoms relieved after receiving a combination of therapy including endoscopic retrograde cholangiopancreatography (ERCP) and somatostatin. He was then discharged after hospitalization for 16 days. For this (the second) admission, he was diagnosed with recurrent pancreatitis and pancreatic pseudocyst based on clinical manifestations, serum amylase and lipase ¢3 times the upper limit of normal, and magnetic resonance imaging findings that revealed an 8.7612.3 cm 2 cyst on the body and tail of the pancreas. The patient received a computed tomography (CT)-guided percutaneous aspiration of the pancreatic pseudocyst 6 days after this admission and a drainage catheter was placed into the pseudocyst for continuous draining. The drainage, dark brown in colour and clear, was sent for culture but did not grow any organisms. The patient remained afebrile until 1 week after the puncture but then developed high-grade fever (.39 u C, axilla temperature) and increasing abdominal pain without additional symptoms. The white blood cell count was 12.53610 9 l 21 with 86 % neutrophils. Drainages collected by puncturing the catheter using sterile syringes were sent for culture on 8 and 9 days after the CT-guided puncture for draining. Both drainage cultures and another one collected by surgical operation later on (see below) grew the same Gram-negative bacilli and coagulase-negative staphylococci (see below for species identification). Repeated cultures of blood did not yield any organisms. Due to the onset of fever and abdominal pain and positive results of drainage cultures, this patient was diagnosed with hospital-acquired peripancreatic infection. Intravenous cefminox (2 g every 12 h) was initiated for empiric therapy until the culture results were available and was then replaced by intravenous moxifloxacin (0.4 g per d) and norvancomycin (0.4 g every 8 h). However, the patient had no response to antimicrobial treatment and received a surgical operation for debriding and draining 15 days after the CT-guided puncture. Approximately 500 ml dark brown pus was drained by surgery and the drainage was sent for culture. Following the surgical draining and meropenem (1 g every 8 h) therapy, the patient's temperature was back to normal and the abdominal pain relieved. One month after the surgery, he was in good condition and discharged.
The coagulase-negative staphylococci were identified as Staphylococcus epidermidis by the MicroScan Walkaway 96 SI (Siemens Healthcare Diagnostic) automated system. The Staph. epidermidis was resistant to oxacillin, ciprofloxacin and trimethoprim/sulphamethoxazole but susceptible to vancomycin, rifampicin, clindamycin and gentamicin. The Gram-negative bacilli were identified as Pseudomonas spp. by the Walkaway system but as Shewanella putrefaciens by the Vitek II (bioMérieux) automated system. The three Gram-negative isolates recovered from three independent cultures displayed the same pattern generated by enterobacterial repetitive intergenic consensus (ERIC) PCR, which was performed as described by Versalovic et al. (1991) . Therefore, the three isolates were actually a single strain, designated WCJ25 here. The species identification was further performed by partially sequencing the 16S rRNA gene amplified with the universal primers 27F and 1492R (Lane, 1991) and the gyrB gene (encoding DNA gyrase subunit B) with primers UP-1 and UP-2r (Yamamoto & Harayama, 1995) . Amplicons were purified using a commercial kit (Omega) and then sequenced using an ABI 3730xl DNA Analyser (Applied Biosystems) at the Beijing Genomics Institute. Similarity searches of the sequences obtained were carried out against the GenBank, EzTaxon (Chun et al., 2007) and LeBIBI (http://pbil.univ-lyon1.fr/bibi/) databases. The 1382 bp 16S rRNA gene sequence of strain WCJ25 was closest (99.6 % identity) to Shewanella xiamenensis type strain S4 and was 98.1 % identical to Shewanella putrefaciens type strain ATCC 8071 (Table 1) . As the 16S rRNA gene sequence sometimes lacks sufficient resolution to differentiate closely related Shewanella species (Huang et al., 2010) , the more rapidly evolving gyrB gene was partially sequenced. The 1167 bp gyrB sequence of strain WCJ25 was 98.5 % identical to that of S. xiamenensis S4 and only 88.1 % identical to that of S. putrefaciens ATCC 8071 (Table 1) . Based on the 16S rRNA gene and gyrB sequences, WCJ25 was identified as S. xiamenensis. Biochemical characteristics (Table 2 ) of WCJ25 were determined using the API 20E and 20NE systems (bioMérieux). Strain WCJ25 exhibited a biochemical pattern similar to that of S. xiamenensis type strain S4 (Huang et al., 2010) , except that WCJ25 did not utilize glucose, arabinose and caprate (Table 2) . WCJ25 was susceptible to amikacin, gentamicin, tobramycin, cefotetan, imipenem, trimethoprim/sulphamethoxazole, levofloxacin, showed intermediate resistance to piperacillin/tazobactam and ciprofloxacin, and resistant to azithromycin, ampicillin, ampicillin-sulbactam, ceftazidime, cefepime, ceftriaxone and ceftizoxime.
Due to the repeated co-isolation of Staph. epidermidis, S. xiamenensis cannot be confirmed as the definite pathogen in this case. Nonetheless, S. xiamenensis is very like to have been the causative pathogen of this peripancreatic infection. The genus Shewanella comprises many species (see http:// www.bacterio.cict.fr/s/shewanella.html). Shewanella species are marine bacteria but have been reported as rare human pathogens (Holt et al., 2005) . The most common Shewanella species associated with human infections are S. algae and S. putrefaciens (Holt et al., 2005) , both of which have been identified as the cause of a variety of infections such as bacteraemia, pneumonia, meningitis and soft tissue infection (Brink et al., 1995; Jorens et al., 2004; Pagani et al., 2003; Tucker et al., 2010; Yilmaz et al., 2007) . However, the species identification of previous reports was generally performed using biochemical reactions or commercially supplied automated microbiology systems. These biochemistry-based methods may be unable to differentiate closely related Shewanella species, as in this case the misidentification of S. xiamenensis as S. putrefaciens by the Vitek II system. It is therefore reasonable to speculate that some previous cases reported as being due to S. putrefaciens may in fact have been caused by other Shewanella species. It seems necessary to employ sequencing of the 16S rRNA and gyrB genes to precisely identify Shewanella isolates to the species level for any incoming reports of cases with Shewanella infection in order to avoid misleading information.
Shewanella isolates have been found previously in various types of clinical samples, including intra-abdominal specimens . However, the source of S. xiamenensis in this case remains undetermined. The patient had no history of contact with seawater, unlike some other cases of Shewanella infection (Holt et al., 2005) . Shewanella was very rarely encountered locally and this case was the only one seen in 3 years, suggesting that the acquisition of S. xiamenensis was unlikely to have been due to patient-topatient transmission. The co-existence of Staph. epidermidis, a skin commensal, indicates a possible external source of S. xiamenensis rather than an internal source such as migration from the gastrointestinal tract. Drainage catheters have been identified as an likely source for Shewanella nosocomial infections (Oh et al., 2008) . It is therefore possible that S. xiamenensis initially colonized the catheter with Staph. epidermidis and later invaded ascendingly, resulting in the peripancreatic infection.
Conclusions
In summary, Shewanella xiamenensis, a newly recognized species from an environmental source, was repeatedly recovered from peripancreatic drainages with Staphylococcus epidermidis and was considered as the probable causative pathogen of peripancreatic infection. Therefore, although it was originally found in sea sediments, S. xiamenensis could also be a rare human pathogen. This report highlights that automatic biochemistry-based methods could misidentify closely related Shewanella species, and that gyrB sequencing is required for species identification of Shewanella clinical isolates. Some previous reported cases with S. putrefaciens infection may actually have been caused by other Shewanella species. 
